141 filings
8-K
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
8-K
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
FGEN
FibroGen Inc
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
FGEN
FibroGen Inc
5 Oct 23
Departure of Directors or Certain Officers
7:41pm
8-K
a3rpes
6 Sep 23
Departure of Directors or Certain Officers
8:55am
8-K
78l6zm9tz3so6wdqoom
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
tb3jba62
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
akjiuzndl58e9r
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
x2pn6pg21z6uwb3go
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
9tbkqpzt4
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
k5f9 j79f
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
bx4rv4e3818
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
hna48ipdyo290nzsn
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
h2er4unvzbbn
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
fu5etj1hhxtylrz
1 May 23
Entry into a Material Definitive Agreement
4:48pm
8-K
jsjka8fguql5ym
27 Feb 23
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
4:06pm
8-K
spri33gdj
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
8-K
swcose5r
8 Aug 22
FibroGen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
dnx61r ik7buwdqr
17 Jun 22
Submission of Matters to a Vote of Security Holders
5:20pm